Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough

Abstract

BACKGROUND: The current characterization of patients with refractory or unexplained chronic cough (RCC and UCC, respectively) primarily stems from relatively small clinical studies. OBJECTIVE: To report the baseline medical history and clinical characteristics of individuals with RCC or UCC who were enrolled in COUGH-1 and COUGH-2, 2 large, global, phase 3 trials of gefapixant, a P2 × 3-receptor antagonist.

Authors

Dicpinigaitis PV; Birring SS; Blaiss M; McGarvey LP; Morice AH; Pavord ID; Satia I; Smith JA; La Rosa C; Li Q

Journal

Annals of Allergy Asthma & Immunology, Vol. 130, No. 1, pp. 60–66

Publisher

Elsevier

Publication Date

January 2023

DOI

10.1016/j.anai.2022.05.003

ISSN

1081-1206

Associated Experts

Imran Satia

Associate Professor, Faculty of Health Sciences

Visit profile

Labels